Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$271.71 USD

271.71
830,236

-0.89 (-0.33%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $271.82 +0.11 (0.04%) 4:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Add Zimmer (ZBH) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Zimmer's (ZBH) potential on its strong segmental and international results for the fiscal fourth quarter.

Zacks Equity Research

Hologic Expands Panther Portfolio With New Product Offerings

by Zacks Equity Research

Hologic's (HOLX) latest offerings are set to improve flexibility and efficiency of laboratories.

Zacks Equity Research

Omnicell (OMCL) Lags Q4 Earnings Estimates, Beats on Revenues

by Zacks Equity Research

Omnicell (OMCL) fourth-quarter 2019 results reflect strong segmental performances.

Zacks Equity Research

ResMed (RMD) Rides on New Product Portfolio, SaaS Growth

by Zacks Equity Research

Within SaaS, ResMed (RMD) consistently gains momentum from the Brightree service portfolio and derives synergies from the accretive MatrixCare buyout.

Zacks Equity Research

Here's Why You Should Add ResMed (RMD) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD), given its strong segmental and international fiscal second-quarter results.

Zacks Equity Research

Zacks.com featured highlights include: MSFT, RUTH, RMD, CDNS, CRL and MXIM

by Zacks Equity Research

Zacks.com featured highlights include: MSFT, RUTH, RMD, CDNS, CRL and MXIM

Zacks Equity Research

ResMed (RMD) Stock Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

ResMed (RMD) is optimistic about maintaining growth momentum on several recent developments.

Zacks Equity Research

Haemonetics (HAE) Q3 Earnings & Revenues Beat, Margins Expand

by Zacks Equity Research

Haemonetics (HAE) fiscal third-quarter 2020 results reflect strong performances in Plasma and Hospital segments.

Zacks Equity Research

Boston Scientific (BSX) Q4 Earnings Beat, Margins Decline

by Zacks Equity Research

Boston Scientific (BSX) is steadily investing in new technologies as well as the global markets, reflecting its uptick in sales across most geographies in Q4.

Zacks Equity Research

Here's Why You Should Retain IDEXX Laboratories Stock Now

by Zacks Equity Research

Investor confidence remains high in IDEXX (IDXX) stock, thanks to solid prospects.

Zacks Equity Research

6 GARP Stocks to Scoop Up for Maximum Returns

by Zacks Equity Research

If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

Zacks Equity Research

ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

ResMed (RMD) exhibits robust growth in the second quarter of fiscal 2020, fueled by the strong performance of both its segment.

Zacks Equity Research

ResMed (RMD) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of 19.80% and 1.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Sriparna Ghosal headshot

COPD Devices Gain Regulatory Go-Ahead: 3 Stocks in Focus

by Sriparna Ghosal

Growth in the COPD devices market can be attributed to factors like steadily rising geriatric population, increasing incidence of smoking and chronic respiratory diseases.

Zacks Equity Research

ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ResMed Launches AirFit F30i CPAP Mask, Widens Client Base

by Zacks Equity Research

ResMed (RMD) launches its first tube-up, full-face CPAP mask, thus completing its full-face mask portfolio.

Zacks Equity Research

NUVA vs. RMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

NUVA vs. RMD: Which Stock Is the Better Value Option?

Zacks Equity Research

Strong Pipeline Aids Tandem Diabetes Despite Stiff Rivalry

by Zacks Equity Research

Tandem Diabetes' (TNDM) products under development comprise AID systems, a next-generation hardware platform and connected (mobile) health offerings.

Zacks Equity Research

Product Launches Aid Intersect ENT (XENT) Despite Cost Woes

by Zacks Equity Research

Intersect ENT (XENT) recently closes its ENCORE study, a small 50-patient open label program designed to evaluate the safety of the repetitive use of SINUVA.

Zacks Equity Research

Bruker (BRKR) Rides High on Strong Nano Sales, New Buyouts

by Zacks Equity Research

Bruker (BRKR) is reaping solid synergy benefits from the acquisitions of Anasys, JPK and Alicona.

Zacks Equity Research

Zimmer Biomet Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Zimmer Biomet (ZBH) is optimistic about maintaining growth momentum on several recent positive developments.

Zacks Equity Research

Neogen (NEOG) Q2 Earnings & Revenues Miss, Margin Rises

by Zacks Equity Research

Neogen Corporation (NEOG) disappoints investors with dismal second-quarter fiscal 2020 results. However, the Food Safety segment showcased a robust performance.

Trina Mukherjee headshot

6 MedTech Stocks That are Set to Beat the Market in 2020

by Trina Mukherjee

Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.

Zacks Equity Research

GNC Holdings Launches Energy Drink With Natural Extracts

by Zacks Equity Research

GNC Holdings (GNC) launches natural ingredient-based energy drink MAD PONY ENERGY.

Zacks Equity Research

Neogen's (NEOG) Soleris for EBAC Receives AOAC's Clearance

by Zacks Equity Research

Neogen's (NEOG) Soleris test gets clearance from the AOAC, paving the way for efficient prevention of food contamination.